Oricell Therapeutics Announces $70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies January 18, 2026
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the US, China and Japan January 18, 2026
MediLink Therapeutics and Roche to develop and commercialize YL201 across numerous solid tumor types January 18, 2026
Bio-Sourcing, Zerion Pharma to Collaborate on First HER2 Oral Monoclonal Antibody for Breast Cancer January 18, 2026
Summit Therapeutics and GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 ADC January 18, 2026
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer January 18, 2026
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop RC148 for Advanced Solid Tumors January 18, 2026
Ferring Pharmaceuticals and Theralase Technologies to Investigate ADSTILADRIN – Ruvidar (TLD-1433) Combo in Bladder Cancer January 18, 2026
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class ADCs for Hard-to-Treat Cancers January 18, 2026
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro January 11, 2026
Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Gen Bispecific ADCs January 11, 2026
STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications January 11, 2026
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies January 11, 2026
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development January 11, 2026
Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration January 11, 2026
Insilico Medicine Announces US$888M Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology January 4, 2026
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates January 4, 2026
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly January 4, 2026
BioAtla and GATC Health Announce a $40M SPV Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ OPSCC January 4, 2026
AbbVie secured global rights outside China to ZG006 (alveltamig) developed by Suzhou Zelgen Biopharmaceuticals January 4, 2026
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates December 30, 2025
